INS.L Regulatory News (INS)

Instem plc("Instem")

Grants Under the Instem Long Term Incentive Plan ('LTIP')

Instem plc (AIM: INS), a leading provider of IT solutions to the global early development healthcare market, announces that Chief Executive Officer, Phil Reason has today been granted options over 150,000 ordinary shares of 10p each ("Ordinary Shares") and Chief Financial Officer, Nigel Goldsmith has been granted options over 100,000 Ordinary Shares under the LTIP.

These share options will become exercisable in 2018, at the nominal value of the Ordinary Shares, subject to meeting company profit targets, pursuant to the rules of the LTIP, which was approved by shareholders at the Annual General Meeting on 21 May 2013

Following these grants of options, Phil Reason and Nigel Goldsmith hold a total of 360,856 and 175,000 share options, respectively and their holdings in Ordinary Shares remain unchanged.

For further information, please contact:

About Instem

Instem is a leading supplier of IT applications to the early development healthcare market, delivering compelling solutions for data collection, management and analysis across the R&D continuum. Instem applications are in use by customers worldwide, meeting the rapidly expanding needs of life science and healthcare organizations for data-driven decision making leading to safer, more effective products.

Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonization of actionable scientific information.

Instem supports over 400 clients through full service offices in the United States, United Kingdom and China with an additional location in India and a full service distributor based in Japan.

To learn more about Instem solutions and its mission, please visit www.instem.com